<DOC>
	<DOCNO>NCT01907607</DOCNO>
	<brief_summary>The treatment advanced GIST patient base imatinib follow sunitinib case resistance/intolerance . However , median progression-free survival ( PFS ) sunitinib frequently short , failure imatinib sunitinib , treatment remain controversial . Previous study GISTs link 9p21 alteration tumor progression ( El-Rifai et al . 2000 ; Kim et al. , 2000 ; Schneider-Stock et al. , 2003 ; Schneider-Stock et al. , 2005 ; Romeo et al . 2009 ; Haller et al. , 2008 ) driver gene positively identify ( CDKN2A , CDKN2B , MTAP ) ( Astolfi et al. , 2010 ; Belinsky et al. , 2009 ; Perrone et al. , 2005 ; Assamaki et al . 2007 ; Huang et al. , 2009 ) . A recent study show homozygous 9p21 deletion target CDKN2A specifically p16INK4a 4 . Most CINSARC gene know transcriptional control E2F . RB1 sequesters E2F , release complex upon RB1 phosphorylation CDK4 . CDK4 , turn , inhibit p16INK4a . Hence , hypothesize alteration restriction point via deletion p16INK4a ( rarely RB1 : 20 % case ) gene GISTs likely causative event lead overexpression CINSARC gene , turn induce chromosome instability ultimately metastasis . Low p16INK4a expression associate response PD-0332991 several vitro tumor model ( Konecny et al . 2011 ; Katsumi et al . 2011 ; Finn et al . 2009 ) . Considering molecular data , believe PD-0332991 warrant clinical investigation advance gastrointestinal stromal tumor alteration p16INK4a . This alteration detectable comparative genomic hybridization technique highly manageable context routine clinical care clinical trial . Exploratory , one-arm , multicenter , phase II clinical trial base twostage Simon 's design To assess antitumor activity PD-0332991 term non-progression 16 week ( centralize review ) patient documented disease progression therapy imatinib sunitinib unresectable and/or metastatic GIST . This multicentre single-arm Phase II study evaluate efficacy safety orally PD-0332991 , 125 mg/day , 21 day on/7 day , patient document disease progression therapy 2nd line sunitinib unresectable and/or metastatic GIST . Indeed , usual treatment advance Gastrointestinal Stromal Tumors Refractory Imatinib Sunitinib best supportive care outcome data already available ( Demetri et al. , 2012 ; Italiano et al. , 2012 ) . Sixty three patient include 10 centre French Sarcoma Group period 18 month enrolment . Patients evaluate scheduled visit three study period : - Pre-treatment ( PRE TT ) : signature inform consent first treatment PD-0332991 . - Treatment ( TT ) : first treatment PD-0332991 first 28 day follow last PD-0332991 administration . - Follow-up ( FUP ) : treatment discontinuation , patient must follow 28 day last dose study drug safety assessment ( AEs and/or SAEs ) .</brief_summary>
	<brief_title>Efficacy Safety PD-0332991 Patients With Advanced Gastrointestinal Stromal Tumors Refractory Imatinib Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year age 2 . Histologically confirm GIST anatomical location confirm RRePS Network ; positive immunohistochemical stain cKIT ( CD117 ) ; negative stain KIT , either positive stain DOG1 identified mutation KIT PDGFRA gene 3 . CDKN2A gene deletion assess arraycomparative genomic hybridization ( arrayCGH ) 4 . Unresectable and/or metastatic disease document progression accord modify RECIST criterion ( see section 7.2.1.5 protocol ) 1st line imatinib 2nd line sunitinib . Progression last line treatment confirm central review two radiological assessment identical ( CT scan MRI ) obtain less 4 month interval within 24 month inclusion . 5 . At least one measurable GIST lesion accord RECIST ( v1.1 Appendix 3 ) . A previously irradiate lesion eligible consider measurable lesion provide objective evidence progression lesion prior start PD0332991 . 6 . A performance status 0 , 1 2 accord Eastern Cooperative Oncology Group ( ECOG ) scale ( Appendix 1 ) 7 . Recovery Grade 2 4 toxicity relate prior line treatment assess accord NCICTCAE v.4.0 ( Appendix 2 ) 8 . Adequate bone marrow function show : Blood absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L 1 . Blood platelet ≥ 100 x 109/L 2 . Blood hemoglobin ( Hgb ) &gt; 9 g/dL 9 . Adequate liver function show : c. Serum plasma ALT AST ≤ 3.0 x ULN ( regardless presence absence metastasis ) d. Serum plasma total bilirubin : ≤ 1.5 x ULN ( excepted patient Gilbert 's syndrome ) 10 . Adequate renal function show serum creatinine ≤ 2 x ULN 11 . Patients give write informed consent obtain accord French European regulation . 12 . Patients affiliate French Social Security 1 . RB1 gene deletion assess arraycomparative genomic hybridization ( arrayCGH ) 2 . Patients receive anticancer drug ≤ 5 day prior start PD0332991 3 . Patients treat plan treat concomitantly cytotoxic antineoplastic treatment , chemotherapy , immunotherapy , biological response modifier , radiotherapy 4 . Patients another primary malignancy within 2 year prior start study drug , exception adequately treat insitu carcinoma uterine cervix , completely excise ( R0 resection ) basal squamous cell carcinoma skin 5 . Patients correct QT interval use Bazett 's formula ( QTcB ) &gt; 470 msec . 6 . Current use anticipate need food drug know strong cytochrome P450 ( CYP ) 3A4 inhibitor ( i.e . grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , posaconazole , erythromycin , clarithromycin , tilithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , nefazodone , diltiazem , delaviridine ) 7 . Patients impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption PD0332991 ( e.g . severe ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , extensive ( &gt; 1m ) small bowel resection , inability swallow oral medication ) . Prior partial gastrectomy exclusion criterion . 8 . Patients prior complete gastrectomy 9 . Any following previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack symptomatic pulmonary embolism . 10 . Patients clinically significant medical surgical condition , accord investigator ' discretion , preclude participation 1. i.e . active uncontrolled infection , uncontrolled diabetes , active chronic liver disease ( cirrhosis , chronic active hepatitis chronic persistent hepatitis ) 2. hepatitis B C virus carrier normal liver function test , include 11 . Known diagnosis human immunodeficiency virus ( HIV ) infection . HIV test mandatory 12 . Patients currently receive anticoagulation treatment therapeutic dos : 1. warfarin equivalent anticoagulant ( e.g . high dose aspirin clopidogrel ) 2. INR &gt; 1.5 . Treatment acetylsalicyclic acid 100 mg daily low molecular weight heparin ( LMWH ) allow 13 . Pregnant breastfeed woman 14 . Women childbearing potential employ two effective method birth control . Effective contraception must use throughout trial 24 week end PD0332991 ( e.g . condom spermicidal jelly , foam suppository film ; diaphragm spermicide ; male condom diaphragm spermicide , oral , implantable , injectable contraceptive ) . Women childbearing potential define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e . menses time precede 12 consecutive month ) , must negative serum pregnancy test ≤ 21 day prior start study drug . 15 . Fertile male willing use contraception state 16 . Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced Gastrointestinal Stromal Tumor Refractory Imatinib Sunitinib</keyword>
	<keyword>PD-0332991</keyword>
	<keyword>Orally</keyword>
	<keyword>Efficacy safety</keyword>
	<keyword>Adult patient</keyword>
	<keyword>Refractory</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Sunitinib</keyword>
</DOC>